DK0831852T3 - Nukleosider med anti-hepatitis B-virusaktivitet - Google Patents
Nukleosider med anti-hepatitis B-virusaktivitetInfo
- Publication number
- DK0831852T3 DK0831852T3 DK96919349T DK96919349T DK0831852T3 DK 0831852 T3 DK0831852 T3 DK 0831852T3 DK 96919349 T DK96919349 T DK 96919349T DK 96919349 T DK96919349 T DK 96919349T DK 0831852 T3 DK0831852 T3 DK 0831852T3
- Authority
- DK
- Denmark
- Prior art keywords
- hepatitis
- nucleosides
- virus activity
- activity
- treatment
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title abstract 2
- 239000002777 nucleoside Substances 0.000 title abstract 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 title 1
- 125000003835 nucleoside group Chemical group 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48571695A | 1995-06-07 | 1995-06-07 | |
PCT/US1996/010026 WO1996040164A1 (en) | 1995-06-07 | 1996-06-07 | Nucleosides with anti-hepatitis b virus activity |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0831852T3 true DK0831852T3 (da) | 2007-03-19 |
Family
ID=23929192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96919349T DK0831852T3 (da) | 1995-06-07 | 1996-06-07 | Nukleosider med anti-hepatitis B-virusaktivitet |
Country Status (11)
Country | Link |
---|---|
US (4) | US6245749B1 (da) |
EP (2) | EP0831852B1 (da) |
JP (2) | JP4413996B2 (da) |
AT (1) | ATE346651T1 (da) |
AU (1) | AU722214B2 (da) |
CA (1) | CA2219132C (da) |
DE (1) | DE69636734T2 (da) |
DK (1) | DK0831852T3 (da) |
ES (1) | ES2276404T3 (da) |
PT (1) | PT831852E (da) |
WO (1) | WO1996040164A1 (da) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6346627B1 (en) * | 1990-02-01 | 2002-02-12 | Emory University | Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers |
AU7954694A (en) | 1993-09-10 | 1995-03-27 | Centre National De La Recherche Scientifique (Cnrs) | Nucleosides with anti-hepatitis b virus activity |
US20020120130A1 (en) | 1993-09-10 | 2002-08-29 | Gilles Gosselin | 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents |
ES2276404T3 (es) * | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
US20030100532A1 (en) | 1997-02-14 | 2003-05-29 | Gary S. Jacob | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections |
CA2322008C (en) * | 1998-02-25 | 2011-06-28 | Emory University | 2'-fluoronucleosides |
KR100886653B1 (ko) | 1998-02-25 | 2009-03-04 | 에모리 유니버시티 | 2'-플루오로뉴클레오사이드 |
EP1754710A3 (en) * | 1998-02-25 | 2007-12-19 | Emory University | 2'-Fluoroncucleosides |
US6531590B1 (en) * | 1998-04-24 | 2003-03-11 | Isis Pharmaceuticals, Inc. | Processes for the synthesis of oligonucleotide compounds |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
DE122007000062I1 (de) | 1998-08-10 | 2007-12-20 | Idenix Cayman Ltd | Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus |
US6458773B1 (en) * | 1998-11-05 | 2002-10-01 | Emory University | Nucleoside with anti-hepatitis B virus activity |
US6407077B1 (en) | 1998-11-05 | 2002-06-18 | Emory University | β-L nucleosides for the treatment of HIV infection |
WO2000047198A2 (en) * | 1999-02-12 | 2000-08-17 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
US6121437A (en) * | 1999-03-16 | 2000-09-19 | Isis Pharmaceuticals, Inc. | Phosphate and thiophosphate protecting groups |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
CN101862345B (zh) | 2000-10-18 | 2014-06-04 | 吉利德制药有限责任公司 | 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物 |
WO2002094844A2 (en) * | 2001-05-18 | 2002-11-28 | Rakesh Kumar | Antiviral nucleosides |
US7049303B2 (en) * | 2001-11-07 | 2006-05-23 | Medical Research Council | Inhibition of viruses |
AU2002360697B2 (en) | 2001-12-20 | 2009-04-23 | Beth Israel Deaconess Medical Center | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation |
SE521676C2 (sv) * | 2002-01-02 | 2003-11-25 | Dilafor Ab | Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet |
TWI244393B (en) | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
JP4173861B2 (ja) | 2002-09-13 | 2008-10-29 | イデニクス(ケイマン)リミテツド | 耐性HBV菌株の治療のためのβ−L−2’−デオキシヌクレオシド及び併用療法 |
CN1293884C (zh) * | 2002-10-29 | 2007-01-10 | 南京长澳医药科技有限公司 | 6-甲氧基双脱氧鸟苷在制备抗乙肝药物中的应用 |
US7151092B2 (en) * | 2002-10-31 | 2006-12-19 | Metabasis Therapeutics, Inc. | Cytarabine monophosphate prodrugs |
WO2004084453A2 (en) | 2003-03-20 | 2004-09-30 | Microbiologica Quimica E Farmaceutica Ltd. | METHODS OF MANUFACTURE OF 2'-DEOXY-β-L-NUCLEOSIDES |
US20040200730A1 (en) * | 2003-04-14 | 2004-10-14 | Kyo Jibiki | Hydrometallurgical copper recovery process |
US7595390B2 (en) | 2003-04-28 | 2009-09-29 | Novartis Ag | Industrially scalable nucleoside synthesis |
EP1639121A4 (en) | 2003-06-30 | 2008-04-16 | Idenix Cayman Ltd | SYNTHESIS OF BETA-L-2-DESOXYNUCLEOSIDES |
NO324263B1 (no) * | 2005-12-08 | 2007-09-17 | Clavis Pharma Asa | Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser |
GB0625283D0 (en) * | 2006-12-19 | 2007-01-24 | Cyclacel Ltd | Combination |
US7951789B2 (en) * | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CA2795054A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2012154321A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013019967A1 (en) * | 2011-08-02 | 2013-02-07 | Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California | Modulators of virus assembly as antiviral agents |
JP6762873B2 (ja) | 2013-09-11 | 2020-09-30 | エモリー・ユニバーシテイ | ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用 |
EP3623364A1 (en) | 2014-02-13 | 2020-03-18 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
JP2017520545A (ja) | 2014-07-02 | 2017-07-27 | リガンド・ファーマシューティカルズ・インコーポレイテッド | プロドラッグ化合物およびそれらの使用 |
JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
WO2022204014A1 (en) * | 2021-03-25 | 2022-09-29 | Per Os Biosciences, Llc. | Compositions and methods for treating coronavirus |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4000137A (en) | 1975-06-10 | 1976-12-28 | American Home Products Corporation | Antitumor derivatives of periodate-oxidized nucleosides |
US4140761A (en) | 1977-04-11 | 1979-02-20 | The United States Of America As Represented By The Department Of Health, Education & Welfare | Modification of hepatitis B virus infection in chronic carriers of hepatitis B surface antigen |
JPS5668674A (en) | 1979-11-08 | 1981-06-09 | Shionogi & Co Ltd | 5-fluorouracil derivative |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
JPS62501712A (ja) | 1985-08-26 | 1987-07-09 | アメリカ合衆国 | 2′、3′―ジデオキシイノシン、2′,3′―ジデオキシグアノシンまたは2′,3′―ジデオキシアデノシンを含有する抗htlv―3/lav剤 |
US4879277A (en) | 1985-08-26 | 1989-11-07 | The United States Of America As Represented By The Department Of Health And Human Services | Antiviral compositions and methods |
GB2181128A (en) | 1985-09-17 | 1987-04-15 | Wellcome Found | 3'-azidonucleosides |
US4916122A (en) | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
US4788181A (en) | 1986-09-29 | 1988-11-29 | The United States Of America As Represented By The Department Of Health And Human Services | 5-substituted-2',3'-dideoxycytidine compounds with anti-HTLV-III activity |
US4963533A (en) | 1986-10-24 | 1990-10-16 | Stichting Rega Vzw (Rega) | Therapeutic application of dideoxycytidinene |
EP0342203B1 (en) | 1987-03-24 | 1994-07-06 | Nycomed Imaging As | 2',3' dideoxyribofuranoxide derivatives |
US5185437A (en) | 1987-04-09 | 1993-02-09 | Burroughs Wellcome Co. | Therapeutic nucleosides |
SE8701605D0 (sv) | 1987-04-16 | 1987-04-16 | Astra Ab | Novel medicinal compounds |
EP0380558A4 (en) | 1987-09-22 | 1991-07-31 | The Regents Of The University Of California | Liposomal nucleoside analogues for treating aids |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5041449A (en) | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
NZ228645A (en) | 1988-04-11 | 1991-09-25 | Iaf Biochem Int | 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections |
US5270315A (en) | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US5466806A (en) | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US4900828A (en) | 1988-05-12 | 1990-02-13 | Hoffmann-Laroche Inc. | Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine |
GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
CA2005815C (en) | 1988-12-19 | 1999-08-03 | Wellcome Foundation Limited (The) | Antiviral acyclic nucleoside derivatives |
ES2196004T3 (es) | 1989-02-08 | 2003-12-16 | Iaf Biochem Int | Procedimiento para preparar 1,3-oxatiolanos sustituidos con propiedades antivirales. |
UA45942A (uk) | 1989-02-08 | 2002-05-15 | Біокем Фарма, Інк. | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція |
NZ233197A (en) | 1989-04-13 | 1991-11-26 | Richard Thomas Walker | Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions |
US5059690A (en) | 1990-03-01 | 1991-10-22 | E. R. Squibb & Sons, Inc. | Purinyl tetrahydrofurans |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
IE904378A1 (en) | 1989-12-20 | 1991-07-03 | Abbott Lab | Analogs of oxetanyl purines and pyrimidines |
US5276151A (en) | 1990-02-01 | 1994-01-04 | Emory University | Method of synthesis of 1,3-dioxolane nucleosides |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
FR2663636B1 (fr) | 1990-06-26 | 1992-10-09 | Centre Nat Rech Scient | Procede de fonctionnalisation d'un oligonucleotide. |
SE9003151D0 (sv) | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5587480A (en) | 1990-11-13 | 1996-12-24 | Biochem Pharma, Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
AU8864191A (en) | 1990-11-13 | 1992-06-11 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties |
US5248776A (en) | 1990-12-05 | 1993-09-28 | University Of Georgia Research Foundation, Inc. | Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides |
US5925643A (en) | 1990-12-05 | 1999-07-20 | Emory University | Enantiomerically pure β-D-dioxolane-nucleosides |
WO1992010496A1 (en) | 1990-12-05 | 1992-06-25 | University Of Georgia Research Foundation, Inc. | ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES |
US5179104A (en) | 1990-12-05 | 1993-01-12 | University Of Georgia Research Foundation, Inc. | Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides |
US5444063A (en) | 1990-12-05 | 1995-08-22 | Emory University | Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
IL100965A (en) * | 1991-02-22 | 1999-12-31 | Univ Emory | 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it |
ATE361293T1 (de) | 1991-03-06 | 2007-05-15 | Univ Emory | Salze und amide von (-) cis 5-fluoro-2'-deoxy-3'- thiacytidine geeignet für die behandlung von hepatitis b |
GB9104740D0 (en) | 1991-03-06 | 1991-04-17 | Wellcome Found | Antiviral nucleoside combination |
WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
GB9110874D0 (en) | 1991-05-20 | 1991-07-10 | Iaf Biochem Int | Medicaments |
ZA923641B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
GB9111902D0 (en) | 1991-06-03 | 1991-07-24 | Glaxo Group Ltd | Chemical compounds |
WO1993000910A1 (en) * | 1991-07-12 | 1993-01-21 | Vical, Inc. | Antiviral liponucleosides: treatment of hepatitis b |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
GB9116601D0 (en) | 1991-08-01 | 1991-09-18 | Iaf Biochem Int | 1,3-oxathiolane nucleoside analogues |
FR2684997A1 (fr) | 1991-12-12 | 1993-06-18 | Centre Nat Rech Scient | Derives de la 9-(beta-d-xylofurannosyl) adenine et de la 1-(beta-d-xylofurannosyl) cytosine, leur preparation et leur application en therapeutique. |
FR2685331A1 (fr) | 1991-12-12 | 1993-06-25 | Centre Nat Rech Scient | Phosphotriesters de la ddu, leur preparation et leur application en therapeutique. |
FR2684996A1 (fr) | 1991-12-12 | 1993-06-18 | Centre Nat Rech Scient | Derives de 2',3'-didesoxy-3'-aminothymidine, leur preparation et leur application en therapeutique. |
US5770725A (en) | 1992-05-25 | 1998-06-23 | Gosselin; Gilles | Phosphotriester type biologically active compounds |
US5849905A (en) | 1994-11-23 | 1998-12-15 | Centre National De La Recherche Scientifique | Biologically active phosphotriester-type nucleosides and methods for preparing same |
FR2692265B1 (fr) | 1992-05-25 | 1996-11-08 | Centre Nat Rech Scient | Composes biologiquement actifs de type phosphotriesters. |
AU4812393A (en) | 1992-09-03 | 1994-03-29 | Biochem Pharma Inc. | Use of rapamycin in the treatment of aids |
GB9226927D0 (en) | 1992-12-24 | 1993-02-17 | Iaf Biochem Int | Dideoxy nucleoside analogues |
FR2705099B1 (fr) | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
JPH08510236A (ja) | 1993-05-12 | 1996-10-29 | カール ワイ. ホステトラー | 局所使用のためのアシクロビル誘導体 |
US5627160A (en) * | 1993-05-25 | 1997-05-06 | Yale University | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents |
TW374087B (en) | 1993-05-25 | 1999-11-11 | Univ Yale | L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents |
EP0631783A1 (en) | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
FR2709754B1 (fr) | 1993-09-10 | 1995-12-01 | Centre Nat Rech Scient | Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale. |
AU7954694A (en) | 1993-09-10 | 1995-03-27 | Centre National De La Recherche Scientifique (Cnrs) | Nucleosides with anti-hepatitis b virus activity |
FR2711655A1 (fr) | 1993-10-21 | 1995-05-05 | Centre Nat Rech Scient | Composés 3'-phosphononucléosides et procédé de préparation. |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
ES2276404T3 (es) | 1995-06-07 | 2007-06-16 | Emory University | Nucleosidos con actividad antivirus de la hepatitis-b. |
US6444652B1 (en) * | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
DE122007000062I1 (de) * | 1998-08-10 | 2007-12-20 | Idenix Cayman Ltd | Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus |
-
1996
- 1996-06-07 ES ES96919349T patent/ES2276404T3/es not_active Expired - Lifetime
- 1996-06-07 WO PCT/US1996/010026 patent/WO1996040164A1/en active IP Right Grant
- 1996-06-07 JP JP50216397A patent/JP4413996B2/ja not_active Expired - Fee Related
- 1996-06-07 PT PT96919349T patent/PT831852E/pt unknown
- 1996-06-07 EP EP96919349A patent/EP0831852B1/en not_active Expired - Lifetime
- 1996-06-07 EP EP05077806A patent/EP1655033A1/en not_active Withdrawn
- 1996-06-07 AU AU61707/96A patent/AU722214B2/en not_active Ceased
- 1996-06-07 DK DK96919349T patent/DK0831852T3/da active
- 1996-06-07 DE DE69636734T patent/DE69636734T2/de not_active Expired - Lifetime
- 1996-06-07 AT AT96919349T patent/ATE346651T1/de active
- 1996-06-07 CA CA002219132A patent/CA2219132C/en not_active Expired - Fee Related
-
1998
- 1998-07-09 US US09/112,878 patent/US6245749B1/en not_active Expired - Lifetime
-
2001
- 2001-06-12 US US09/879,854 patent/US7468357B2/en not_active Expired - Fee Related
-
2005
- 2005-07-12 US US11/180,964 patent/US20050277616A1/en not_active Abandoned
-
2007
- 2007-03-23 JP JP2007077327A patent/JP2007204485A/ja active Pending
-
2008
- 2008-12-15 US US12/316,627 patent/US20090105185A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2276404T3 (es) | 2007-06-16 |
DE69636734D1 (de) | 2007-01-11 |
JP4413996B2 (ja) | 2010-02-10 |
JPH11507381A (ja) | 1999-06-29 |
WO1996040164A1 (en) | 1996-12-19 |
CA2219132A1 (en) | 1996-12-19 |
US20090105185A1 (en) | 2009-04-23 |
CA2219132C (en) | 2007-03-06 |
US6245749B1 (en) | 2001-06-12 |
ATE346651T1 (de) | 2006-12-15 |
US7468357B2 (en) | 2008-12-23 |
AU722214B2 (en) | 2000-07-27 |
EP0831852A1 (en) | 1998-04-01 |
US20050277616A1 (en) | 2005-12-15 |
EP0831852B1 (en) | 2006-11-29 |
DE69636734T2 (de) | 2007-10-18 |
EP0831852A4 (en) | 1999-03-31 |
EP1655033A1 (en) | 2006-05-10 |
PT831852E (pt) | 2007-02-28 |
JP2007204485A (ja) | 2007-08-16 |
US20020107221A1 (en) | 2002-08-08 |
AU6170796A (en) | 1996-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0831852T3 (da) | Nukleosider med anti-hepatitis B-virusaktivitet | |
DE69232649T2 (de) | Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b | |
ZA97721B (en) | Methods for retreatment of patients afflicted with hepatitis C using consensus interferon. | |
EP1852121A3 (en) | Lipid analogs for treating viral infections | |
TWI317735B (en) | Methods and compositions for treating hepatitis c virus | |
IL153078A0 (en) | Methods for treating hepatitis delta virus infection with beta-l-2' deoxy nucleosides | |
DK0775007T3 (da) | Blodbehandlingsindretning med forbedret udbytte, og som har en vinklet grænsestyreflade | |
ATE481135T1 (de) | Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen | |
DE69823984D1 (de) | Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden | |
DK1284720T3 (da) | L-FMAU til behandling af hepatitis delta-virusinfektion | |
DE68912155D1 (de) | Antivirales Kombinationspräparat. | |
BR9913951A (pt) | Tratamento de infecção de hepatite b com timosina alfa 1 em combinação com lamivudina e flamciclovir | |
NO953473D0 (no) | Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling | |
DE69718911D1 (de) | Interleukin - 8 als antivirale- und antitumorwirkstoffe | |
WO2004006843A3 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
RU92016478A (ru) | Способ диагностики гепатита, способ лечения гепатита |